Recon: AbbVie to purchase Gilgamesh’s psychedelic therapy for potential $1.2B; FDA pauses Valneva's chikungunya vaccine license

• As MAHA turns 1, a fired-up movement is still figuring out how to fulfill its promises (STAT)
• AbbVie to buy Gilgamesh’s psychedelic drug for up to $1.2 billion (STAT)
• FDA says it will publish reports of adverse events tied to drugs on daily basis (STAT)
• US CDC taps vaccine skeptic to lead COVID vaccine committee (Reuters)
• FDA suspends license for Valneva's chikungunya vaccine amid safety concerns (Endpoints)

• China screened 600 million for disease, keeping up COVID-era controls (Reuters)
• Botswana Declares Health Crisis as Low Diamond Demand Hits State Medical Funds (Bloomberg)
• MedTech Europe sounds alarm over impact of US-EU tariffs on patients (MedTech Dive)
• German Health Researchers Prep for Possible Disruptions to PubMed, ClinicalTrials.gov (MedTech Insight)

• Gene-edited pig lung transplanted into a brain-dead patient for first time (STAT)
• Testosterone made me feel 30 again — until it nearly broke my heart (STAT)
• The future of medicine lies in multifunctional therapies (STAT)
• Merck looks to modest HIV business as a $5B underdog (Endpoints)
• Akeso reports positive Phase 3 readouts from two inflammation-tackling antibodies (Endpoints)
• BeOne to get $885M upfront in royalty deal over Amgen’s Imdelltra (Endpoints)
• MannKind to buy scPharmaceuticals for up to $360M; Arnatar launches with $52M (Endpoints)
• LB Pharmaceuticals seeks IPO as cash runs dry for looming Phase 3 schizophrenia trial (Endpoints)
• Biotechs Turn to Digital Coins, Crypto to Boost Stock Prices (Bloomberg)
• Mitsubishi Is Said to Near Investment in Fullerton Health (Bloomberg)
• With late-stage trial win, Argenx preps FDA filing to push Vyvgart into broader myasthenia gravis population (Fierce Pharma)

• He was 21 when he programmed MyChart. Now he’s the president of Epic (STAT)
• Terumo Buying Organ Tech Provider OrganOx for $1.5 Billion (Bloomberg)
• Ransomware attack on DaVita exposes data from 2.7M (MedTech Dive)
• The robotic surgery market battle is heating up (MedTech Dive)

• Grocers’ meat departments show resilience amid economic woes: report (Food Dive)
• Foodservice sector navigates headwinds (Food Business News)

• Amid cries for retraction, a medical journal reviews a discredited, 24-year-old paper on an antidepressant (STAT)
• Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug (Reuters)
• Ozempic teeth: Dentists warn of new GLP-1 side effect (The Hill)
• HHS derecognizing unions representing staffers at CDC, FDA, NIH and more (The Hill)